Votrient for metastatic renal cell carcinoma - Details

Détails

Fichiers
Generic Name:
Pazopanib hydrochloride
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Renal Cell Carcinoma
Fabricant:
GlaxoSmithKline Inc.
Brand Name:
Votrient
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0000-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
200 mg
Tumour Type:
Genitourinary
Indications:
Metastatic renal cell carcinoma
Funding Request:
First-line therapy in patients with metastatic renal cell (clear cell) carcinoma who have a Memorial Sloan Kettering Prognostic Score of Favourable or Intermediate Risk
Review Status:
Complete
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Couvrir le remboursement
Clarification:
The manufacturer, GlaxoSmithKline Inc. has resubmitted to pCODR for Pazopanib Hydrochloride (Votrient) submission. Please see the Pazopanib hydrochloride (Votrient) for Metastatic Renal Cell Carcinoma Resubmission Details page for more information
Clarification:
.
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.